Literature DB >> 15759260

Retrospective family study of childhood medulloblastoma.

David Ng1, Theodora Stavrou, Ling Liu, Michael D Taylor, Bert Gold, Michael Dean, Michael J Kelley, Elizabeth C Dubovsky, Gilbert Vezina, H S Nicholson, Julianne Byrne, James T Rutka, David Hogg, Gregory H Reaman, Alisa M Goldstein.   

Abstract

Medulloblastoma is the most common malignant central nervous system tumor of childhood and can occur sporadically or in association with inherited cancer susceptibility syndromes such as the nevoid basal cell carcinoma syndrome (NBCCS). To determine whether an association existed between the risk of developing medulloblastoma and undiagnosed syndromes, we retrospectively reviewed clinical data on 33 patients with medulloblastoma from a single institution and compared them with their unaffected relatives (n = 46). Six patients had tumors showing desmoplastic histology. Two of the six met diagnostic criteria for NBCCS. One NBCCS patient had a missense mutation of patched-1 (PTCH1); the other had no identifiable PTCH1 mutation. Two patients with isolated desmoplastic medulloblastoma had an insertion and splice site mutation, respectively, in suppressor of fused (SUFU). All patients with nondesmoplastic medulloblastoma histology received molecular testing for SUFU. None of these patients had an identifiable mutation in PTCH1 or SUFU. We performed a clinical evaluation for Greig cephalopolysyndactyly syndrome (GCPS) in four medulloblastoma families, who exhibited macrocephaly as the only finding consistent with the diagnosis of GCPS. Molecular analysis of GLI3 in these four families was negative. There was a paucity of clinical findings among the majority of medulloblastoma patients in this study group to suggest a definable cancer genetic syndrome. We conclude that clinically recognizable syndromes are uncommon among patients with medulloblastoma, however, PTCH1 and SUFU mutations are present at a low but significant frequency. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759260     DOI: 10.1002/ajmg.a.30653

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  10 in total

1.  Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma.

Authors:  Ingrid Slade; Anne Murray; Sandra Hanks; Ajith Kumar; Lisa Walker; Darren Hargrave; Jenny Douglas; Charles Stiller; Louise Izatt; Nazneen Rahman
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.

Authors:  Léa Guerrini-Rousseau; Christelle Dufour; Pascale Varlet; Julien Masliah-Planchon; Franck Bourdeaut; Marine Guillaud-Bataille; Rachid Abbas; Anne-Isabelle Bertozzi; Fanny Fouyssac; Sophie Huybrechts; Stéphanie Puget; Brigitte Bressac-De Paillerets; Olivier Caron; Nicolas Sevenet; Marina Dimaria; Sophie Villebasse; Olivier Delattre; Dominique Valteau-Couanet; Jacques Grill; Laurence Brugières
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  Nestin Mediates Hedgehog Pathway Tumorigenesis.

Authors:  Peng Li; Eric H Lee; Fang Du; Renata E Gordon; Larra W Yuelling; Yongqiang Liu; Jessica M Y Ng; Hao Zhang; Jinhua Wu; Andrey Korshunov; Stefan M Pfister; Tom Curran; Zeng-Jie Yang
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

4.  PCDH10 is a candidate tumour suppressor gene in medulloblastoma.

Authors:  Kelsey C Bertrand; Stephen C Mack; Paul A Northcott; Livia Garzia; Adrian Dubuc; Stefan M Pfister; James T Rutka; William A Weiss; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2011-05-20       Impact factor: 1.475

Review 5.  Molecular mechanisms of suppressor of fused in regulating the hedgehog signalling pathway.

Authors:  Dengliang Huang; Yiting Wang; Jiabin Tang; Shiwen Luo
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 6.  The molecular genetics of medulloblastoma: an assessment of new therapeutic targets.

Authors:  Carlos G Carlotti; Christian Smith; James T Rutka
Journal:  Neurosurg Rev       Date:  2008-06-12       Impact factor: 3.042

7.  Multiple skin hamartomata: a possible novel clinical presentation of SUFU neoplasia syndrome.

Authors:  Kirsty Mann; Jill Magee; Marine Guillaud-Bataille; Christophe Blondel; Brigitte Bressac-de Paillerets; Josie Yeatman; Ingrid Winship
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

Review 8.  The clinical implications of medulloblastoma subgroups.

Authors:  Paul A Northcott; Andrey Korshunov; Stefan M Pfister; Michael D Taylor
Journal:  Nat Rev Neurol       Date:  2012-05-08       Impact factor: 42.937

9.  Itch/β-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis.

Authors:  Paola Infante; Roberta Faedda; Flavia Bernardi; Francesca Bufalieri; Ludovica Lospinoso Severini; Romina Alfonsi; Daniela Mazzà; Mariangela Siler; Sonia Coni; Agnese Po; Marialaura Petroni; Elisabetta Ferretti; Mattia Mori; Enrico De Smaele; Gianluca Canettieri; Carlo Capalbo; Marella Maroder; Isabella Screpanti; Marcel Kool; Stefan M Pfister; Daniele Guardavaccaro; Alberto Gulino; Lucia Di Marcotullio
Journal:  Nat Commun       Date:  2018-03-07       Impact factor: 14.919

Review 10.  Molecular Bases of Human Malformation Syndromes Involving the SHH Pathway: GLIA/R Balance and Cardinal Phenotypes.

Authors:  Yo Niida; Sumihito Togi; Hiroki Ura
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.